<?xml version="1.0" encoding="UTF-8"?>
<p id="par0055">The first approach is repurposing of broadly acting antiviral drugs that have been used for other viral infections or other indications. These drugs have the obvious benefits of being already available with known pharmacokinetic and pharmacodynamic properties, solubility, metabolic stability, side effects, and dosing regimens. Drugs including interferon α, β, and γ, ribavirin (
 <bold>1</bold>) and inhibitors of cyclophilin 
 <xref rid="bib0300" ref-type="bibr">60</xref>, 
 <xref rid="bib0305" ref-type="bibr">61</xref>, 
 <xref rid="bib0310" ref-type="bibr">62</xref> were discovered using this approach.
</p>
